Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 5ruxolitinib 3Sirolimus 3Mycophenolic Acid 3fludarabine 2asciminib 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1montelukast 1axatilimab 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Specimen Handling 1Saline Solution 1Rituximab 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Panobinostat 1Methotrexate 1Mesna 1Infliximab 1Imatinib Mesylate 1Everolimus 1Erythropoietin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Beclomethasone × 1 year × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡